



# TFOS meeting - Cernobbio, Italy

15 minute talks, 10 minute discussion

Impact of glaucoma medications on the ocular surface\* and how ocular surface disease can influence glaucoma treatment

#### Moderators

- · Christophe Baudouin (Quinze-Vingts National Eye Hospital & Vision Institute, Paris, France)
- · Miriam Kolko (Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen; Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark)
- · David A Sullivan (TFOS, and recently Schepens Eye Research Institute & Harvard Medical School, Boston, MA)
- \* The term "ocular surface" encompasses the surface (cornea & conjunctiva), tear film, and adnexa (lacrimal and meibomian glands).

### Opening remarks

8:00 Amy Gallant Sullivan (Executive Director, Tear Film & Ocular Surface Society, Boston, MA, USA)

#### Introduction


8:05 TFOS: Global mission - David A Sullivan

Epidemiology, pathophysiology and treatment of glaucoma

8:20 Epidemiology and pathophysiology of glaucoma -Gus Gazzard (Moorfields Eve Hospital, London, UK) 8:45 Therapeutic approaches for glaucoma treatment: Generics

versus brand-named drugs -Miriam Kolko

Sponsored by:










Impact of topical glaucoma medications on the ocular surface and adnexa 9:10 Prevalence of, and risk factors for, ocular surface disease in glaucoma patients -Elisabeth Messmer (Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany) 9:35 Adverse effects of active ingredients in glaucoma medications on the ocular surface and adnexa - Fredrik Fineide and Tor Paaske Utheim (Department of Ophthalmology, Oslo University Hospital, Oslo, Norway) 10:00 Adverse effects of active ingredients in glaucoma medications on the nasolacrimal duct and periorbital area -Rachna Murthy (Face Restoration, London, UK)

10:40 Adverse effects of BAK preservatives in glaucoma medications - Françoise Brignole-Baudouin (Institut de la Vision, Sorbonne Université, Paris, France) 11:05 Adverse effects of non-BAK preservatives in glaucoma medications - Anton Hommer (Department of Ophthalmology, HERA Hospital, Vienna, Austria) 11:30 Adverse effects of antimetabolite treatments following glaucoma filtration surgery - Gus Gazzard 11:55 Treatment outcomes: Tolerability, compliance and quality of life - Andrew J Tatham (Princess Alexandra Eye Pavilion and Department of Ophthalmology, University of Edinburgh, Edinburgh, United Kingdom) 12:20 Lunch











Impact of pre-existing ocular surface disease on glaucoma treatment - both surgical and medical

1:50 Management of ocular surface disease in glaucoma patients - Christophe Baudouin (Quinze-Vingts National Eye Hospital & Vision Institute, Paris, France)

2:15 Management of glaucoma in ocular surface disease patients -Barbara Cvenkel (Ljubljana University Medical Centre, Ljubljana, Slovenia)

## Therapeutic challenges

2:40 Bottleneck in bottle design -Sofie Beier (School of Design, The Royal Danish Academy of Fine Arts, Copenhagen, Denmark) 3:05 How could we improve glaucoma treatment care - the way to the heart of the politician -Marijke Vittrup (Chief Executive Officer, Fight for Sight, Denmark)

3:30 Point of view of glaucoma treatment from a patient with ocular surface disease - Erik Jespersen (Denmark) 3:55 Coffee/tea Future research

recommendations

4:15 Anne Hedengran Nagstrup (Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen; Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark)

4:20 Fredrik Fineide (Department of Ophthalmology, Oslo University Hospital, Oslo, Norway)

Conclusions & closing remarks 4:25 Miriam Kolko

Sponsored by:















## REGISTRATION

Registration Fee: Euro 60,00 VAT Included

Meeting, Lunch and 2 Coffee Breaks included

For registration: http://reg.jaka.it/index.php





